ES2325642T3 - Anticuerpos recombinantes genicos. - Google Patents

Anticuerpos recombinantes genicos. Download PDF

Info

Publication number
ES2325642T3
ES2325642T3 ES99921206T ES99921206T ES2325642T3 ES 2325642 T3 ES2325642 T3 ES 2325642T3 ES 99921206 T ES99921206 T ES 99921206T ES 99921206 T ES99921206 T ES 99921206T ES 2325642 T3 ES2325642 T3 ES 2325642T3
Authority
ES
Spain
Prior art keywords
flt
vegf receptor
relates
present
recombinant antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99921206T
Other languages
English (en)
Inventor
Kenya Shitara
Mikito Ito
Yoko Kawada
Kazuyasu Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2325642T3 publication Critical patent/ES2325642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo recombinante génico que (i) reacciona específicamente con el receptor Flt-1 de VEGF humano, (ii) reconoce un epítopo presente en una zona definida por la secuencia de aminoácidos del terminal N constituido por los restos de aminoácidos 1 a 338 del receptor Flt-1 de VEGF humano incluyendo su secuencia señal y (iii) inhibe la unión de VEGF humano al receptor Flt-1 de VEGF humano, en el que la secuencia de aminoácidos de la zona V de la cadena H del anticuerpo recombinante génico comprende las secuencias de aminoácidos de SEC. ID. nº: 5, nº: 6 y nº: 7 o las secuencias de aminoácidos de SEC. ID. nº: 11, nº: 12 y nº: 13 como RDC, y la secuencia de aminoácidos de la zona V de la cadena L del anticuerpo recombinante génico comprende las secuencias de aminoácidos de SEC. ID. nº: 8, nº: 9 y nº: 10 o las secuencias de aminoácidos de SEC. ID. nº: 14, nº: 15 y nº: 16 como RDC, con la condición de que el anticuerpo monoclonal KM1732 depositado con el número de registro FERM BP-5698 y el anticuerpo monoclonal KM1750 depositado con el número de registro FERM BP-5700 se excluyan.
ES99921206T 1998-05-20 1999-05-20 Anticuerpos recombinantes genicos. Expired - Lifetime ES2325642T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13900098 1998-05-20

Publications (1)

Publication Number Publication Date
ES2325642T3 true ES2325642T3 (es) 2009-09-10

Family

ID=15235143

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99921206T Expired - Lifetime ES2325642T3 (es) 1998-05-20 1999-05-20 Anticuerpos recombinantes genicos.

Country Status (7)

Country Link
EP (1) EP1086956B1 (es)
AT (1) ATE428732T1 (es)
AU (1) AU767731B2 (es)
CA (1) CA2328986A1 (es)
DE (1) DE69940733D1 (es)
ES (1) ES2325642T3 (es)
WO (1) WO1999060025A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3475100A (en) * 1999-01-29 2000-08-18 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
GB0323609D0 (en) * 2003-10-09 2003-11-12 Univ Belfast A peptide,and use of the peptide to assay for sflt-1 protein
WO2005035581A1 (ja) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ヒトVEGF受容体Flt-1に特異的に結合する抗体組成物
WO2005121338A1 (ja) * 2004-06-07 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ抗体
CA2590671A1 (en) 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1
TWI478940B (zh) * 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
KR100998569B1 (ko) * 2008-03-31 2010-12-07 한국원자력연구원 암 또는 전이암 진단 및 치료용 방사면역접합체，및 이를이용한 암 또는 전이암 억제제 개발

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
JP3565572B2 (ja) * 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
ATE331806T1 (de) * 1996-11-21 2006-07-15 Kyowa Hakko Kogyo Kk Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.

Also Published As

Publication number Publication date
AU3850399A (en) 1999-12-06
WO1999060025A1 (fr) 1999-11-25
EP1086956A4 (en) 2002-08-21
CA2328986A1 (en) 1999-11-25
AU767731B2 (en) 2003-11-20
EP1086956A1 (en) 2001-03-28
ATE428732T1 (de) 2009-05-15
EP1086956B1 (en) 2009-04-15
DE69940733D1 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
EP0882799A4 (en) AGAINST HUMAN VEGF RECEPTOR FLT-1, MONOCLONAL ANTIBODY.
HRP20190333T1 (hr) Cd20 protutijela s povećanim afinitetom vezanja fc-receptora i povećanom efektorskom funkcijom
Horn et al. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein: evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
ES2325642T3 (es) Anticuerpos recombinantes genicos.
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER